Evidence map›Paper›PMID 32427134›Full record

ReviewBrain, behavior, & immunity - health2020

How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up.

Michael Ogier, Guillaume Andéol, Emmanuel Sagui, Gregory Dal Bo

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Brain, behavior, & immunity - health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06156241 (Long COVID), which is not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06156241 phase1unknown statusnot on this mapstarted 2024, after this paper: background citation

Long COVID: Cord Tissue-Derived Mesenchymal Stromal Cells for Persistent NeuroInflammatory Symptoms

TypeinterventionalSponsorCharles CoxRan2024 to 2026Enrolled12ConditionsPost-Acute COVID-19 SyndromeArmsStem Cell
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Hearing Loss, Tinnitus, and Dizziness in COVID-19: A Systematic Review and Meta-Analysis.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2022
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. COVID-19 and Auditory Dysfunctions: A Relatively Rare but Important Symptom.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. SARS-CoV-2 Morbidity in the CNS and the Aged Brain Specific Vulnerability.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Rehabilitation During COVID-19 Pandemic: An Indian Perspective.Disaster medicine and public health preparedness · 2022
    Article
  18. Article
  19. Neurological complications and infection mechanism of SARS-COV-2.Signal transduction and targeted therapy · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael OgierFrench Armed Forces Biomedical Research Institute, 1 place Valérie André, 91220, Brétigny sur Orge, France.
Guillaume AndéolFrench Armed Forces Biomedical Research Institute, 1 place Valérie André, 91220, Brétigny sur Orge, France.
Emmanuel SaguiFrench Armed Forces Biomedical Research Institute, 1 place Valérie André, 91220, Brétigny sur Orge, France.
Gregory Dal BoFrench Armed Forces Biomedical Research Institute, 1 place Valérie André, 91220, Brétigny sur Orge, France.
Service de Santé des Armées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review intends to provide an overview of the current knowledge on neurologic sequelae of COVID-19 and their possible etiology, and, based on available data, proposes possible improvements in current medical care procedures. We conducted a thorough review of the scientific literature on neurologic manifestations of COVID-19, the neuroinvasive propensity of known coronaviruses (CoV) and their possible effects on brain structural and functional integrity. It appears that around one third of COVID-19 patients admitted to intensive care units (ICU) for respiratory difficulties exhibit neurologic symptoms. This may be due to progressive brain damage and dysfunction triggered by severe hypoxia and hypoxemia, heightened inflammation and SARS-CoV-2 dissemination into brain parenchyma, as suggested by current reports and analyses of previous CoV outbreaks. Viral invasion of the brain may particularly target and alter brainstem and thalamic functions and, consequently, result in sensorimotor dysfunctions and psychiatric disorders. Moreover, data collected from other structurally homologous CoV suggest that SARS-CoV-2 infection may lead to brain cell degeneration and demyelination similar to multiple sclerosis (MS). Hence, current evidence warrants further evaluation and long-term follow-up of possible neurologic sequelae in COVID-19 patients. It may be particularly relevant to evaluate brainstem integrity in recovered patients, as it is suspected that this cerebral area may particularly be dysfunctional following SARS-CoV-2 infection. Because CoV infection can potentially lead to chronic neuroinflammation and progressive demyelination, neuroimaging features and signs of MS may also be evaluated in the long term in recovered COVID-19 patients.

Indexed as

Auditory brainstem responsesBrainstem dysfunctionCOVID-19Cytokine stormMicroglia primingMultiple sclerosisNeuroimagingNeuroinflammatory mechanismsNeurologic sequelaeSARS-CoV-2

Identifiers

PMID32427134
PMCPMC7227537
OpenAlexW3025232440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.